There are 2949 resources available
1330P - Discontinuation of ICIs above 18 months of treatment in real-life patients with NSCLC: A multicentric retrospective study
Presenter: Geoffroy Bilger
Session: E-Poster Display
Resources:
Abstract
1331P - Correlation between development and grade of immune-related toxicities and outcomes during treatment with immune checkpoint inhibitors in non-small cell lung cancer patients
Presenter: Pablo Ayala de Miguel
Session: E-Poster Display
Resources:
Abstract
1332P - Prognostic value of baseline and dynamic change value of CTC in advanced NSCLC patients treated with immune checkpoint inhibitor-based therapy
Presenter: Guanghui Gao
Session: E-Poster Display
Resources:
Abstract
1333P - The influence of polypharmacy on outcome in real life non-small cell lung cancer (NSCLC) patients treated with immunotherapy
Presenter: Birgitte Bjoernhart
Session: E-Poster Display
Resources:
Abstract
1334P - Real word experience with first-line immunotherapy in advanced non-small cell lung cancer patients in a Danish nationwide cohort
Presenter: Mette Mouritzen
Session: E-Poster Display
Resources:
Abstract
1335P - Anti-tumour efficacy of cetuximab plus avelumab in NSCLC through induction of ADCC: Final data from CAVE-lung trial
Presenter: Morena Fasano
Session: E-Poster Display
Resources:
Abstract
1336P - Patients with EGFR exon 20 insertion mutation non-small cell lung cancer benefit from pemetrexed-based chemotherapy: A multicenter study
Presenter: Wenxian Wang
Session: E-Poster Display
Resources:
Abstract
1337P - The clincial utility of circulating free DNA (cfDNA) analysis in non-small cell lung cancer (NSCLC) in the United Kingdom
Presenter: Alastair Greystoke
Session: E-Poster Display
Resources:
Abstract
1338P - Molecular characteristics and response to immunotherapy in Chinese NSCLC patients with HER2 alterations
Presenter: Zhengbo Song
Session: E-Poster Display
Resources:
Abstract
1339P - Clinicopathological characteristics and treatment patterns observed in real-world care in patients with advanced non-small cell lung cancer (NSCLC) and KRAS G12C mutations in the Flatiron Health (FH)-Foundation Medicine (FMI) Clinico-Genomic Database (CGDB)
Presenter: Shivani Aggarwal
Session: E-Poster Display
Resources:
Abstract